344: Off-the-Shelf Tumor Immunotherapy with Genetically Enhanced Allogeneic T-Cell Precursors

Abstract

T cell deficiencies can occur in many physiological and pathophysiological settings such as aging, malignant diseases, and cytostatic therapy. We recently reported that co-transplantation of in vitro generated T cell precursors significantly enhances T cell reconstitution after allogeneic HSCT resulting in increased graft-versus-tumor activity without graft-versus-host disease. The aim of our present study was to evaluate if allogeneic T cell precursors can safely be transferred across MHC barriers in the absence of allogeneic HSCs to improve anti-tumor activity in immunosuppressed recipients.